Barrett's esophagus in females: A comparative analysis of risk factors in females and males

Department of Surgery and Cardiothoracic Surgery, Keck School of Medicine, The University of Southern California, Los Angeles, California, USA.
The American Journal of Gastroenterology (Impact Factor: 9.21). 04/2005; 100(3):560-7. DOI: 10.1111/j.1572-0241.2005.40962.x
Source: PubMed

ABSTRACT Gastroesophageal reflux symptoms occur with similar frequency in males and females, yet Barrett's esophagus is less common in females. The reason for this disparity is unknown. The aim of this study was to determine the factors related to Barrett's in females.
The records of 796 patients (462 male, 334 female) evaluated from 1990 to 2000 for symptoms of reflux were retrospectively reviewed. Physiologic abnormalities based on results of endoscopic, motility, pH, and Bilitec testing were identified, and factors related to the presence of Barrett's were determined using univariate and multivariate analysis.
Females with reflux symptoms were significantly less likely to have a positive 24-h pH test, a defective lower esophageal sphincter, or a hiatal hernia than males with reflux symptoms. Further, females with reflux on the basis of an abnormal 24-h pH test had significantly less esophageal acid exposure than males with reflux. In contrast, esophageal exposure to refluxed acid and bilirubin was similar in females (n = 50) and males (n = 136) with Barrett's. On multivariable analysis increased esophageal bilirubin exposure was the only significant factor associated with the presence of Barrett's in male and female patients with reflux disease.
Females with reflux symptoms have less esophageal acid exposure on average than males. However, females and males with Barrett's have a similar severity of reflux, and the female gender does not protect against the development of Barrett's in the setting of advanced reflux disease. Esophageal bilirubin exposure is the major risk factor for the presence of Barrett's in patients with reflux disease.

Download full-text


Available from: Guilherme Campos, Aug 01, 2015
  • Source
    • "Therapeutic Advances in Gastroenterology that this qualitative measurement of obesity may be an even stronger risk factor for Barrett's than BMI. Banki's study also demonstrated that patients with documented bile reflux were five to eleven times more likely to have Barrett's esophagus [Banki et al. 2005]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Barrett's esophagus, or the presence of specialized intestinal mucosa in the esophagus that has a malignant potential, has experienced a rapid increase in diagnosis and prevalence over the past few decades. Once thought to progress to adenocarcinoma in an orderly sequence of increasing dysplasia, recent data suggest the process can be more random. In combination with targeted surveillance endoscopy, recent improvements in technology have aided endoluminal therapy in becoming a cost-effective adjunct to medication. When used in combination, in particular, these ablative therapies have become suitable, if not preferable, alternatives to surgery in many patients.
    Therapeutic Advances in Gastroenterology 09/2008; 1(2):121-42. DOI:10.1177/1756283X08095883
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Die vorliegende Arbeit untersucht die Genotoxizität des Tabakalkaloids Myosmin mit Hilfe des Comet-Assays in der humanen Ösophagus-Adenokarzinomzelllinie OE33. Der Comet-Assay weist in seiner alkalischen Form Einzel- und Doppelstrangbrüche der DNA, sowie alkalilabile Stellen und DNA-Fragmente, die bei der Excisionsreparatur entstehen nach. Als wichtigster Risikofaktor für die Entstehung von Adenokarzinomen im Ösophagus gilt der Barrett-Ösophagus, bei dem es durch Reflux von Säure und Duodenalinhalten aus dem Magen zu Entzündungen kommt. Um die so im Ösophagus auftretenden Bedingungen abzubilden, wurden die OE33-Zellen zum einen bei sauren pH-Werten mit Myosmin allein oder gleichzeitig mit Myosmin und verschiedenen reaktiven Spezies behandelt. Dies führte zu einer Steigerung der durch Myosmin verursachten, im Comet-Assay nachweisbaren DNA-Schäden. Außerdem konnte gezeigt werden, dass Myosmin die Reparatur methylierter DNA in OE33-Zellen hemmt. Die genotoxische Wirkung von Myosmin beruht wahrscheinlich auf der Induktion von 4-Hydroxy-1-(3-pyridyl)-1-butanon (HPB) freisetzenden DNA-Addukten. Diese Addukte werden außerdem von den als kanzerogen für den Menschen eingestuften Tabakspezifischen Nitrosaminen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanon (NNK) und Nitrosonornicotin (NNN) verursacht. Myosmin kann zum einen zu NNN nitrosiert werden, das nach metabolischer Aktivierung HBP-Addukte verursachen kann. Darüber hinaus kann es durch Nitrosierung bzw. Peroxidierung aber auch direkt zu reaktiven Metaboliten umgesetzt werden, die HPB-Addukte bilden.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The difficulties in designing an effective load autopilot for missile arise from highly nonlinear and non-minimum phase plant characteristics from load command to missile load output. In this paper, the method of designing controller relied upon the notion of system immersion and manifold invariance. The construction of the stabilizing control laws resembles the procedure used in nonlinear regulator theory to derive the (invariant) output zeroing manifold and its friend. The method is well suited in situations where we know a stabilizing controller of a nominal reduced order mode, which we would like to robustify with respect to higher order dynamics. This method overcomes these difficulties and the designed autopilot improves system performances.
    Intelligent Control and Automation, 2004. WCICA 2004. Fifth World Congress on; 07/2004
Show more